RESUMO
The aim of the study was to determine the prevalence of anti-hepatitis A virus (anti-HAV) antibodies among 172 children with chronic liver disease, and to calculate the cost-effectiveness of prescreening prior to hepatitis A vaccination. Anti-HAV antibodies were positive in 85.1%. However, seroprevalence of anti-HAV antibodies was 62.1% in children < 5 years and 94.4% in children 5+ years. We conclude that while it is cost-effective to do prescreening before hepatitis A vaccination for children with chronic liver disease aged 5+ years, prescreening might not be cost-effective in those aged < 5 years.
Assuntos
Hepatite A/diagnóstico , Hepatite A/prevenção & controle , Hepatopatias/virologia , Programas de Rastreamento/economia , Vacinação/economia , Distribuição por Idade , Fatores Etários , Estudos de Casos e Controles , Distribuição de Qui-Quadrado , Criança , Pré-Escolar , Doença Crônica , Análise Custo-Benefício , Egito/epidemiologia , Diretrizes para o Planejamento em Saúde , Hepatite A/complicações , Hepatite A/epidemiologia , Anticorpos Anti-Hepatite A/sangue , Humanos , Programas de Imunização , Programas de Rastreamento/métodos , Vigilância da População , Avaliação de Programas e Projetos de Saúde , Estudos Soroepidemiológicos , Vacinação/métodosRESUMO
The aim of the study was to determine the prevalence of anti-hepatitis A virus [anti-HAV] antibodies among 172 children with chronic liver disease, and to calculate the cost- effectiveness of prescreening prior to hepatitis A vaccination. Anti-HAV antibodies were positive in 85.1%. However, seroprevalence of anti-HAV antibodies was 62.1% in children < 5 years and 94.4% in children 5+ years. We conclude that while it is cost-effective to do prescreening before hepatitis A vaccination for children with chronic liver disease aged 5+ years, prescreening might not be cost-effective in those aged < 5 years
